The global bleeding disorders testing market was valued at USD 102.0 million in 2024 and is expected to grow from USD 109.8 million in 2025 to approximately USD 189.7 million by 2032, reflecting a compound annual growth rate (CAGR) of 8.1% over the forecast period. In 2024, North America led the market, accounting for a 40.2% share of the global revenue.
The bleeding disorders testing market is witnessing steady growth, driven by increasing awareness, improved diagnostic technologies, and a rising prevalence of inherited and acquired bleeding conditions. Advancements in molecular and genetic testing are enabling earlier and more accurate diagnoses, which is crucial for effective disease management. Government initiatives and healthcare programs supporting rare disease detection are also contributing to greater testing adoption. While developed regions benefit from established diagnostic infrastructure, emerging markets are showing growing potential due to improving healthcare access and rising public health investments.
Learn more here:
https://www.fortunebusinessinsights.com/bleeding-disorder-testing-market-106908
Market Segmentation
By Type of Disorder
The market covers testing for various bleeding disorders including hemophilia A, hemophilia B, von Willebrand disease, and other rare clotting factor deficiencies. Hemophilia A remains the most commonly tested condition, while increasing awareness is improving diagnosis rates for lesser-known disorders.
By Test Type
Common tests include activated partial thromboplastin time (aPTT), prothrombin time (PT), fibrinogen tests, genetic testing, and factor assays. Molecular and genetic tests are gaining prominence due to their ability to provide more accurate diagnoses and inform targeted treatments.
By End User
End users primarily include hospitals, diagnostic laboratories, research institutions, and specialty clinics. Diagnostic labs and hospitals perform most routine tests, while research institutions contribute to advanced genetic and molecular studies in bleeding disorders.
List of Top Bleeding Disorders Testing Companies:
Hoffmann-La Roche Ltd. (Switzerland)
Siemens Healthcare GmbH (Germany)
HORIBA Ltd. (Japan)
Sysmex Corporation (Japan)
Abbott (U.S.)
Thermo Fisher Scientific Inc. (U.S.)
Atlas Medical GmbH (Germany)
HYPHEN BioMed (France)
Precision Biologics (U.S.)
Market Growth Drivers
The bleeding disorder testing market is expanding due to the rising prevalence of inherited and acquired bleeding disorders, as well as improved awareness and early diagnosis. The advancement of diagnostic technologies, including molecular testing and point-of-care solutions, is significantly enhancing detection accuracy and turnaround time. Government support and initiatives, particularly in newborn screening and rare disease programs, are also fueling demand for comprehensive testing. Additionally, increased research and development activities are contributing to better understanding and identification of various bleeding disorders.
Market Restraining Factors
Despite positive trends, several factors limit the market’s full potential. High testing costs, particularly for advanced genetic diagnostics, can limit accessibility in low-resource settings. Limited awareness among the general population and primary healthcare providers often leads to underdiagnosis or misdiagnosis. In certain regions, insufficient infrastructure and skilled personnel restrict the adoption of advanced diagnostic techniques. Additionally, reimbursement challenges and regulatory hurdles can delay the implementation of new testing technologies in clinical practice.
Regional Analysis
North America dominates the bleeding disorder testing market due to strong diagnostic infrastructure, high awareness levels, and widespread availability of advanced testing technologies. Supportive insurance and government programs also contribute to high diagnosis rates.
Europe follows closely, benefiting from robust healthcare systems and government-backed screening initiatives. Countries in Western Europe have well-established diagnostic protocols for bleeding disorders, while Central and Eastern Europe are gradually improving access.
Asia-Pacific represents a growing market driven by increased healthcare investment, rising awareness, and the large population base. Improvements in diagnostic capabilities and growing focus on rare disease management are supporting market expansion.
In Latin America, the market is steadily growing as awareness improves and public health systems begin to integrate bleeding disorder diagnostics into routine care. However, disparities in healthcare infrastructure remain a challenge.
The Middle East & Africa region shows gradual growth, supported by international collaborations, improving laboratory infrastructure, and increasing attention toward rare diseases. However, market growth is still limited by access and affordability barriers in several countries.